BACKGROUND: Hemoglobin-based oxygen-carrying solutions (HBOC) provide emergency alternatives to blood transfusion to carry oxygen to tissues without the risks of disease transmission or transfusion reaction. Two primary concerns hampering the clinical acceptance of acellular HBOC are the occurrence of systemic and pulmonary vasoconstriction and the maintenance of the heme-iron in the reduced state (Fe2+). We recently demonstrated that pretreatment with inhaled nitric oxide prevents the systemic hypertension induced by HBOC-201 (polymerized bovine hemoglobin) infusion in awake mice and sheep without causing methemoglobinemia. However, the impact of HBOC-201 infusion with or without inhaled nitric oxide on pulmonary vascular tone has not yet been examined. METHODS: The pulmonary and systemic hemodynamic effects of breathing nitric oxide both before and after the administration of HBOC-201 were determined in healthy, awake lambs. RESULTS: Intravenous administration of HBOC-201 (12 ml/kg) induced prolonged systemic and pulmonary vasoconstriction. Pretreatment with inhaled nitric oxide (80 parts per million [ppm] for 1 h) prevented the HBOC-201--induced increase in mean arterial pressure but not the increase of pulmonary arterial pressure, systemic vascular resistance, or pulmonary vascular resistance. Pretreatment with inhaled nitric oxide (80 ppm for 1 h) followed by breathing a lower concentration of nitric oxide (5 ppm) during and after HBOC-201 infusion prevented systemic and pulmonary vasoconstriction without increasing methemoglobin levels. CONCLUSIONS: These findings demonstrate that pretreatment with inhaled nitric oxide followed by breathing a lower concentration of the gas during and after administration of HBOC-201 may enable administration of an acellular hemoglobin substitute without vasoconstriction while preserving its oxygen-carrying capacity.
BACKGROUND: Hemoglobin-based oxygen-carrying solutions (HBOC) provide emergency alternatives to blood transfusion to carry oxygen to tissues without the risks of disease transmission or transfusion reaction. Two primary concerns hampering the clinical acceptance of acellular HBOC are the occurrence of systemic and pulmonary vasoconstriction and the maintenance of the heme-iron in the reduced state (Fe2+). We recently demonstrated that pretreatment with inhaled nitric oxide prevents the systemic hypertension induced by HBOC-201 (polymerized bovine hemoglobin) infusion in awake mice and sheep without causing methemoglobinemia. However, the impact of HBOC-201 infusion with or without inhaled nitric oxide on pulmonary vascular tone has not yet been examined. METHODS: The pulmonary and systemic hemodynamic effects of breathing nitric oxide both before and after the administration of HBOC-201 were determined in healthy, awake lambs. RESULTS: Intravenous administration of HBOC-201 (12 ml/kg) induced prolonged systemic and pulmonary vasoconstriction. Pretreatment with inhaled nitric oxide (80 parts per million [ppm] for 1 h) prevented the HBOC-201--induced increase in mean arterial pressure but not the increase of pulmonary arterial pressure, systemic vascular resistance, or pulmonary vascular resistance. Pretreatment with inhaled nitric oxide (80 ppm for 1 h) followed by breathing a lower concentration of nitric oxide (5 ppm) during and after HBOC-201 infusion prevented systemic and pulmonary vasoconstriction without increasing methemoglobin levels. CONCLUSIONS: These findings demonstrate that pretreatment with inhaled nitric oxide followed by breathing a lower concentration of the gas during and after administration of HBOC-201 may enable administration of an acellular hemoglobin substitute without vasoconstriction while preserving its oxygen-carrying capacity.
Authors: Scott C Dorman; Clare F Kenny; Lee Miller; Rhoda Elison Hirsch; John P Harrington Journal: Artif Cells Blood Substit Immobil Biotechnol Date: 2002-01
Authors: D R Morel; E Lowenstein; T Nguyenduy; D R Robinson; J E Repine; D E Chenoweth; W M Zapol Journal: Circ Res Date: 1988-05 Impact factor: 17.367
Authors: H Krieter; G Hagen; K F Waschke; A Köhler; B Wenneis; U B Brückner; K van Ackern Journal: J Cardiothorac Vasc Anesth Date: 1997-02 Impact factor: 2.628
Authors: Binglan Yu; Michael J Raher; Gian Paolo Volpato; Kenneth D Bloch; Fumito Ichinose; Warren M Zapol Journal: Circulation Date: 2008-04-07 Impact factor: 29.690
Authors: Pedro Cabrales; George Han; Parimala Nacharaju; Adam J Friedman; Joel M Friedman Journal: Am J Physiol Heart Circ Physiol Date: 2010-11-05 Impact factor: 4.733
Authors: Binglan Yu; Mohd Shahid; Elena M Egorina; Mikhail A Sovershaev; Michael J Raher; Chong Lei; Mei X Wu; Kenneth D Bloch; Warren M Zapol Journal: Anesthesiology Date: 2010-03 Impact factor: 7.892
Authors: Binglan Yu; Francesco Zadek; Anna Fischbach; Steffen B Wiegand; Lorenzo Berra; Donald B Bloch; Warren M Zapol Journal: Nitric Oxide Date: 2020-01-23 Impact factor: 4.427
Authors: David M Baron; Binglan Yu; Chong Lei; Aranya Bagchi; Arkadi Beloiartsev; Christopher P Stowell; Andrea U Steinbicker; Rajeev Malhotra; Kenneth D Bloch; Warren M Zapol Journal: Anesthesiology Date: 2012-03 Impact factor: 7.892
Authors: Arkadi Beloiartsev; Maria da Glória Rodrigues-Machado; Guo Ling Zhou; Timothy C Tan; Luca Zazzeron; Robert E Tainsh; Patricio Leyton; Rosemary C Jones; Marielle Scherrer-Crosbie; Warren M Zapol Journal: Am J Respir Cell Mol Biol Date: 2015-05 Impact factor: 6.914